MRNS Marinus Pharmaceuticals
- 1.435
- +0.025+1.77%
Marinus Pharmaceuticals News
Press Release: Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 RADNOR, Pa.--(BUSINESS WIRE)--May 01, 2024-- Marinus Pharmaceuticals, Inc. (Nasdaq:
How Is The Market Feeling About Marinus Pharma?
Marinus Pharma's (NYSE:MRNS) short percent of float has fallen 3.64% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 6.35% of all regular shar
Market Cool On Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Revenues Pushing Shares 84% Lower
The Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) share price has fared very poorly over the last month, falling by a substantial 84%. For any long-term shareholders, the last month ends a year to fo
Marinus Pharmaceuticals Price Target Cut to $10.00/Share From $25.00 by Truist Securities
Marinus Pharmaceuticals Price Target Cut to $10.00/Share From $25.00 by Truist Securities
Truist Securities: Maintaining Marinus Pharma (MRNS.US) rating, adjusted from buy to buy rating, and adjusted target price from $25.00 to $10.00.
Truist Securities: Maintaining Marinus Pharma (MRNS.US) rating, adjusted from buy to buy rating, and adjusted target price from $25.00 to $10.00.
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri
Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird
Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird
Marinus Pharmaceuticals Cut to Neutral From Outperform by Baird
Marinus Pharmaceuticals Cut to Neutral From Outperform by Baird
Baird: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to a neutral rating, and the target price was adjusted from $20.00 to $2.00.
Baird: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to a neutral rating, and the target price was adjusted from $20.00 to $2.00.
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
HC Wainwright & Co. : Marinus Pharma (MRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $27.00.
HC Wainwright & Co. : Marinus Pharma (MRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $27.00.
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Marinus Pharma (NASDAQ:MRNS) with a Buy and maintains $27 price target.
Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics Among Healthcare Movers
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Marinus Pharmaceuticals Price Target Cut to $3.00/Share From $24.00 by RBC Capital
Marinus Pharmaceuticals Price Target Cut to $3.00/Share From $24.00 by RBC Capital
Royal Bank of Canada: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to being equal to the general market, and the target price was adjusted from $24.00 to $3.00.
Royal Bank of Canada: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to being equal to the general market, and the target price was adjusted from $24.00 to $3.00.
RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
RBC Capital analyst Brian Abrahams downgrades Marinus Pharma from Outperform to Sector Perform and lowers the price target from $24 to $3.
Marinus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 125.56% RBC Capital $24 → $3 Downgrades Outperform → Sector Perform 04/10/2024 2005.26% Cantor
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Analysis
Price Target
No Data
